Marlies van Zwam-van der Wijk, Jeroen J Roor, Rudolf Ponds, Lars de Vroege
{"title":"躯体症状及相关疾病(SSRD)患者的治疗效果、有效性和结果。","authors":"Marlies van Zwam-van der Wijk, Jeroen J Roor, Rudolf Ponds, Lars de Vroege","doi":"10.1080/23279095.2024.2445715","DOIUrl":null,"url":null,"abstract":"<p><p>This study addresses the relationship between performance validity and treatment outcome in a sample of patients with somatic symptom and related disorders (SSRD). A retrospective analysis was performed in a sample of 337 patients with SSRD who received treatment. Interaction effects were determined between performance validity test (PVT) performance and raw change scores, reliable change index and clinical change of depression, anxiety and physical symptoms. Performance validity was measured by using the Test of Memory Malingering (TOMM). There was no significant difference between the PVT pass and PVT fail groups in change in depression, anxiety and physical symptoms after treatment. Both groups exhibited a comparable reduction in their symptoms of depression, anxiety and physical symptoms after treatment. There was also no association between PVT performance and raw change scores, reliable clinical changes and clinical changes on depression, anxiety, and physical symptoms. Performance validity was not related to treatment outcome in patients with SSRD, which is a clinically relevant finding. Further studies may want to look into other relevant aspects for determining the potential impact of performance (in)validity on treatment outcome in patients with SSRD, such as treatment drop-out or the number of missed/attended treatment sessions. Alternatively, as treatment outcome is usually determined based on patients' self-report, the impact that non-credible symptom reporting (i.e., symptom validity test failure) has on treatment outcomes is a logical next step for understating the impact of response bias beyond the testing session.</p>","PeriodicalId":51308,"journal":{"name":"Applied Neuropsychology-Adult","volume":" ","pages":"1-8"},"PeriodicalIF":1.4000,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Performance validity and outcome of treatment in patients with somatic symptom and related disorders (SSRD).\",\"authors\":\"Marlies van Zwam-van der Wijk, Jeroen J Roor, Rudolf Ponds, Lars de Vroege\",\"doi\":\"10.1080/23279095.2024.2445715\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This study addresses the relationship between performance validity and treatment outcome in a sample of patients with somatic symptom and related disorders (SSRD). A retrospective analysis was performed in a sample of 337 patients with SSRD who received treatment. Interaction effects were determined between performance validity test (PVT) performance and raw change scores, reliable change index and clinical change of depression, anxiety and physical symptoms. Performance validity was measured by using the Test of Memory Malingering (TOMM). There was no significant difference between the PVT pass and PVT fail groups in change in depression, anxiety and physical symptoms after treatment. Both groups exhibited a comparable reduction in their symptoms of depression, anxiety and physical symptoms after treatment. There was also no association between PVT performance and raw change scores, reliable clinical changes and clinical changes on depression, anxiety, and physical symptoms. Performance validity was not related to treatment outcome in patients with SSRD, which is a clinically relevant finding. Further studies may want to look into other relevant aspects for determining the potential impact of performance (in)validity on treatment outcome in patients with SSRD, such as treatment drop-out or the number of missed/attended treatment sessions. Alternatively, as treatment outcome is usually determined based on patients' self-report, the impact that non-credible symptom reporting (i.e., symptom validity test failure) has on treatment outcomes is a logical next step for understating the impact of response bias beyond the testing session.</p>\",\"PeriodicalId\":51308,\"journal\":{\"name\":\"Applied Neuropsychology-Adult\",\"volume\":\" \",\"pages\":\"1-8\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2025-01-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Applied Neuropsychology-Adult\",\"FirstCategoryId\":\"102\",\"ListUrlMain\":\"https://doi.org/10.1080/23279095.2024.2445715\",\"RegionNum\":4,\"RegionCategory\":\"心理学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Applied Neuropsychology-Adult","FirstCategoryId":"102","ListUrlMain":"https://doi.org/10.1080/23279095.2024.2445715","RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
本研究探讨躯体症状及相关疾病(SSRD)患者表现效度与治疗结果之间的关系。对337例接受治疗的SSRD患者进行回顾性分析。观察成绩效度测验(PVT)成绩与抑郁、焦虑和躯体症状的原始变化得分、可靠变化指数和临床变化之间的交互效应。效能效度采用记忆伪造测验(Test of Memory Malingering, TOMM)进行测量。PVT通过组和PVT失败组治疗后抑郁、焦虑和躯体症状的变化无显著差异。治疗后,两组患者的抑郁、焦虑和身体症状均有相当程度的减轻。PVT表现与原始变化评分、可靠的临床变化以及抑郁、焦虑和身体症状的临床变化之间也没有关联。SSRD患者的效能效度与治疗结果无关,这是一个具有临床相关性的发现。进一步的研究可能需要研究其他相关方面,以确定表现效度对SSRD患者治疗结果的潜在影响,例如治疗退出或错过/参加治疗的次数。另外,由于治疗结果通常是根据患者的自我报告确定的,因此不可信的症状报告(即症状效度测试失败)对治疗结果的影响是低估反应偏倚在测试阶段之后的影响的合乎逻辑的下一步。
Performance validity and outcome of treatment in patients with somatic symptom and related disorders (SSRD).
This study addresses the relationship between performance validity and treatment outcome in a sample of patients with somatic symptom and related disorders (SSRD). A retrospective analysis was performed in a sample of 337 patients with SSRD who received treatment. Interaction effects were determined between performance validity test (PVT) performance and raw change scores, reliable change index and clinical change of depression, anxiety and physical symptoms. Performance validity was measured by using the Test of Memory Malingering (TOMM). There was no significant difference between the PVT pass and PVT fail groups in change in depression, anxiety and physical symptoms after treatment. Both groups exhibited a comparable reduction in their symptoms of depression, anxiety and physical symptoms after treatment. There was also no association between PVT performance and raw change scores, reliable clinical changes and clinical changes on depression, anxiety, and physical symptoms. Performance validity was not related to treatment outcome in patients with SSRD, which is a clinically relevant finding. Further studies may want to look into other relevant aspects for determining the potential impact of performance (in)validity on treatment outcome in patients with SSRD, such as treatment drop-out or the number of missed/attended treatment sessions. Alternatively, as treatment outcome is usually determined based on patients' self-report, the impact that non-credible symptom reporting (i.e., symptom validity test failure) has on treatment outcomes is a logical next step for understating the impact of response bias beyond the testing session.
期刊介绍:
pplied Neuropsychology-Adult publishes clinical neuropsychological articles concerning assessment, brain functioning and neuroimaging, neuropsychological treatment, and rehabilitation in adults. Full-length articles and brief communications are included. Case studies of adult patients carefully assessing the nature, course, or treatment of clinical neuropsychological dysfunctions in the context of scientific literature, are suitable. Review manuscripts addressing critical issues are encouraged. Preference is given to papers of clinical relevance to others in the field. All submitted manuscripts are subject to initial appraisal by the Editor-in-Chief, and, if found suitable for further considerations are peer reviewed by independent, anonymous expert referees. All peer review is single-blind and submission is online via ScholarOne Manuscripts.